Dr. Scott Gottlieb: CVS Health-Aetna deal, others may hinder generic drug entries

FDA Commissioner Scott Gottlieb, MD, expressed concern over the consolidating pharmacy benefit manager market and drug supply chain March 28 at CNBC's Healthy Returns conference in New York, according to Reuters.

Dr. Gottlieb said transactions like the CVS Health-Aetna or Cigna-Express Scripts deals could make it easier for drugmakers to limit access to cheaper generic drugs that compete with their own brand-name products.

"We don't have direct purview over it, but we do have something to say about it, and we're going to be speaking to the PBMs about it," Dr. Gottlieb said at the conference, according to Reuters.

The FDA head also shared the agency's plans to create about a dozen policies to encourage more competition between expensive biotech medicines and their biosimilar versions.

More articles on supply chain:

Study: 40% of providers have canceled surgeries over supply shortages
10 immensely overinflated hospital costs
California leads way on drug pricing transparency with other states poised to follow: 6 things to know

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.